Population pharmacokinetics and pharmacodynamics: Potential use for gathering dose-concentration-response

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 21, Issue 2, 1996, Pages 113-121

  Jerling, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adverse effects; Nortriptyline; Pharmacodynamics; Pharmacogenetics; Population pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ALIMEMAZINE; ALPRAZOLAM; CARBAMAZEPINE; DEXTROPROPOXYPHENE; FLUNITRAZEPAM; FLUPENTIXOL; LEVOMEPROMAZINE; NITRAZEPAM; NORTRIPTYLINE; PERPHENAZINE; PROPIOMAZINE; THIORIDAZINE;

ADULT; AGED; CONCENTRATION RESPONSE; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MONITORING; EYE DISEASE; FEMALE; HUMAN; HYPOSALIVATION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; TACHYCARDIA;

EID: 0030035909     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190259     Document Type: Conference Paper

References (51)

1. Jerling M., Bertilsson L., Sjöqvist F. (1994) : The use of therapeutic drug monitoring data to document kinetic drug interactions: the example with amitriptyline and nortriptyline. Ther. Drug Monit., 16, 1-12.
2. Jerling M., Alván G. (1994) : Nonlinear kinetics of nortriptyline in relation to nortriptyline clearance as observed during therapeutic drug monitoring. Eur. J. Clin. Pharmacol., 46, 67-70.
3. Jerling M., Merlé Y., Mentré F., Mallet A. (1994) : Population pharmacokinetics of nortriptyline during monotherapy and during concomitant therapy with dmgs that inhibit CYP2D6 -an evaluation with the nonparametric maximum likelihood method. Br. J. Clin. Pharmacol., 38, 453-462.
4. Jerling M. (1996) : Dosing of antidepressants - the unknown art. J. Clin. Psychopharmacol., In press.
5. Alexanderson B., Borgå O., Alván G. (1973) : The availability of orally administered nortriptyline. Eur. J. Clin. Pharmacol., 5, 181-185.
6. Gram L., Fredricson Overø K. (1975) : First-pass metabolism of nortriptyline in man. Clin. Pharmacol. Ther., 18, 305-314.
7. Alexanderson B. (1972) : Pharmacokinetics of nortriptyline in man after single and multiple oral doses: the predictability of steady-state plasma concentrations from single-dose plasma-level data. Eur. J. Clin. Pharmacol., 4, 82-91.
8. Alexanderson B., Evans D.A.P., Sjoqvist F. (1969) : Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. BMJ, 4, 764-768.
9. Kragh-Sørensen P., Larsen N.E. (1980) : Factors influencing nortriptyline steady-state kinetics: Plasma and saliva levels. Clin. Pharmacol. Ther., 28, 796-803.
10. Dawling S., Crome P., Braithwaite R. (1980) : Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers. Clin. Pharmacokinet., 5, 394-401.
11. Kumar V., Smith R.C., Reed K., Leelavathi D E. (1987) : Plasma levels and effects of nortriptyline in geriatric depressed patients. Acta Psych. Scand., 75, 20-28.
12. Kanba S., Matsumoto K., Nibuya M., et al. (1992) : Nortriptyline response in elderly depressed patients. Prog. Neuro-Psychopharmacol. Bio-Psychiatr., 16, 301-309.
13. Turbott J., Norman T.R., Burrows G.D., Maguire K.P., Davies B.M. (1980) : Pharmacokinetics of nortriptyline in elderly volunteers. Commun. Psychopharmacol, 4, 225-231.
14. Katz I.R, Simpson G.M., Jethanandani V., Cooper T., Muhly C. (1989) : Steady state pharmacokinetics of nortriptyline in the frail elderly. Neuropsychopharmacology, 2, 229-236.
15. Smith R.C., Reed K., Leelavathi D.E. (1980) : Pharmacokinetics and the effects of nortriptyline in geriatric depressed patients. Psychopharmacol. Bull., 16, 54-57.
16. Perry P.J., Browne J.L., Prince R.A., Alexander B., Tsuang M.T. (1986) : Effects of smoking on nortriptyline plasma concentrations in depressed patients. Ther. Drug Monit., 8, 279-284.
17. Dawling S., Lynn K., Rosser R., Braithwaite R. (1982) : Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clin. Pharmacol. Ther., 32, 322-329.
18. Alexanderson B., Bertilsson L. (1972) : Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady-state level. Eur. J. Clin. Pharmacol., 4, 201-205.
19. Alexanderson B., Borgå O. (1973) : Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple doses. Eur. J. Clin. Pharmacol., 5, 174-180.
20. Bertilsson L., Eichelbaum M., Mellström B., Sawe J., Schultz H-U., Sjoqvist F. (1980) : Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci., 27, 1673-1677.
21. Woolhouse N.M., Adjepon-Yamoah K.K., Mellström B., Hedman A., Bertilsson L., Sjoqvist F. (1984) : Nortriptyline and debrisoquine hydroxylarion in Ghanaian and Swedish subjects. Clin. Pharmacol. Ther., 36, 374-378.
22. Bertilsson L., Dabl M.L., Sjöjqvist F., et al. (1993) : Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine (letter). Lancet, 341, 63.
23. Johansson I., Lundqvist E., Bertilsson L., Dabl M.L., Sjöqvist F., Ingelman-Sundberg M. (1993) : Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA, 90, 11825-11829.
24. Gram L.F., Fredricson Overø K. (1972) Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. BMJ, 1, 463-465.
25. Inaba T., Jurima M., Mahon W.A., Kalow W. (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos., 13, 443-448.
26. Syvälahti E.K., Lindberg R., Kallio J., De Vocht M. (1986) : Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br. J. Clin. Pharmacol., 22, 89-92.
27. Gram L.F., Debruync D., Caillard V., et al. (1989) : Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br. J. Clin. Pharmacol., 27, 272-275.
28. Spina E., Martines C., Caputi A.P., et al. (1991) : Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur. J. Clin. Pharmacol., 41, 467-470.
29. Åsberg M., Cronholm B., Sjöqvist F., Tuck D. (1971) : Relationship between plasma level and therapeutic effect of nortriptyline. BMJ, 3, 331-334.
30. Kragh-Sørensen P., Åsberg M , Eggert-Hansen C. (1973) : Plasma-nortriptyline levels in endogenous depression. Lancet, 1, 113-115.
31. Kragh-Sørensen P., Eggert-Hansen C., Baastrup P.C., Hvidberg E.F. (1976) : Self-inhibiting action of nortriptylines antidepressive effect at high plasma levels. Psychopharmacologia (Berl.), 45, 305-312.
32. Ziegler V.E., Clayton P.J., Taylor J.R., Co B.T., Biggs J.T. (1976) : Nortriptyline plasma levels and therapeutic response. Clin. Pharmacol. Ther., 20, 458-463.
33. Montgomery S.A., Braithwaite R.A., Dawling S., McAuley R. (1978) : High plasma nortriptyline levels in the treatment of depression. Clin. Pharmacol. Ther., 23, 309-314.
34. Bertilsson L., Mellström B., Sjöqvist F. (1979) : Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci., 15, 1285-1292.
35. Thayssen P., Bjerre M., Kragh-Sørensen P., et al. (1981) : Cardiovascular effects of imipramine and nortriptyline in elderly patients. Psyehopharmacology, 74, 360-364.
36. Kragh-Sørensen P. (1985) : Monitoring plasma concentration of nortriptyline. Dan. Med. Bull., 32, 29-53.
37. Åsberg M., Germanis M. (1972) : Ophthalmological effect of nortriptyline - relationship to plasma level. Pharmacology, 7, 349-356.
38. Mallet A. (1986) : A maximum likelihood estimation method for random coefficient regression models. Biometrika, 3, 645-656.
39. Mallet A., Mentré F., Gilles J., et al. (1988) : Handling covariates in population pharmacokinetics, with an application to Gentamicin. Biomed. Meas. Inform. Conti., 2, 138-146.
40. Thomson A.H., Whiting B. (1992) : Bayesian parameter estimation and population pharmacokinetics. Clin. Pharmacokinet., 22, 447-467.
41. Sheiner L.B., Beal S.L. (1981) : Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm., 9, 503-512.
42. Brøsen K., Kragh-Sørensen P. (1993) : Concomitant intake of nortriptyline and carbamazepine. Ther. Drug Monit., 15, 258-260.
43. Dahl M.L., Johansson I., Bertilsson L., Ingelman-Sundberg M., Sjöqvist F. (1996) : Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther., In press.
44. Kehoe W.A., Harralson A.F., Kwentus J A., Jacisin J.J., Sheffel W.B., Hetnal M.J. (1991) : Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model. DICP, 25, 1368-1373.
45. Kehoe W.A., Harralson A.F., Jacisin J.J., Duong T.T. (1994) : Sources of prediction error when using a Bayesian method to evaluate nortriptyline serum concentrations. J. Clin. Pharmacol., 34, 842-847.
46. Mentré F., Mallet A., Steimer J.L., Lokiec F. (1988) : An application of population pharmacokinetics to the clinical use of cyclosporine in bone marrow transplant patients. Transplant Proc., 20, 466-470.
47. Bjerre M., Gram L.F., Kragh-Sørensen P., et al. (1981) : Dose-dependent kinetics of imipramine in elderly patients. Psychopharmacology, 75, 354-357.
48. Sindrup S.H., Brøsen K., Gram L.F. (1992) : Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin. Pharmacol. Ther., 51, 288-295.
49. Taright N., Mentré F., Mallet A., Jouvent R. (1994) : Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new Bayesian approach. Ther. Drug Monit., 16, 258-269.
50. Balant L.P., Rowland M., Aarons L., et al. (1993) : New strategies in drug development and clinical evaluation: the population approach. Commentary on an action for co-operative research. Eur. J. Clin. Pharmacol., 45, 93-94.
51. Peck C.C., Barr W.H., Benet L.Z., et al. (1994) : Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J. Clin. Pharmacol., 34, 111-119.